NeuClone Makes Progress On Ustekinumab
Reports Positive Phase I Results; Phase III Trial To Begin In 2021
Australia’s NeuClone expects to be among the first biosimilar market entrants to challenge Stelara, with the firm’s NeuLara ustekinumab rival reporting positive Phase I data as the company prepares to move ahead with Phase III trials next year.
